- Home
- BCSF vs RCUS Comparison
BCSF vs RCUS Comparison
Compare BCSF & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- RCUS
- Stock Information
- Founded
- BCSF 2015
- RCUS 2015
- Country
- BCSF United States
- RCUS United States
- Employees
- BCSF N/A
- RCUS N/A
- Industry
- BCSF Finance/Investors Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- RCUS Health Care
- Exchange
- BCSF Nasdaq
- RCUS Nasdaq
- Market Cap
- BCSF 978.9M
- RCUS 906.4M
- IPO Year
- BCSF 2018
- RCUS 2018
- Fundamental
- Price
- BCSF $15.28
- RCUS $10.23
- Analyst Decision
- BCSF Buy
- RCUS Buy
- Analyst Count
- BCSF 2
- RCUS 8
- Target Price
- BCSF $16.50
- RCUS $20.86
- AVG Volume (30 Days)
- BCSF 259.4K
- RCUS 855.1K
- Earning Date
- BCSF 08-05-2025
- RCUS 08-07-2025
- Dividend Yield
- BCSF 10.99%
- RCUS N/A
- EPS Growth
- BCSF N/A
- RCUS N/A
- EPS
- BCSF 1.75
- RCUS N/A
- Revenue
- BCSF $284,993,000.00
- RCUS $141,000,000.00
- Revenue This Year
- BCSF N/A
- RCUS N/A
- Revenue Next Year
- BCSF N/A
- RCUS $28.73
- P/E Ratio
- BCSF $8.74
- RCUS N/A
- Revenue Growth
- BCSF N/A
- RCUS N/A
- 52 Week Low
- BCSF $13.20
- RCUS $6.50
- 52 Week High
- BCSF $19.21
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- BCSF 48.47
- RCUS 64.20
- Support Level
- BCSF $15.16
- RCUS $9.14
- Resistance Level
- BCSF $15.82
- RCUS $9.62
- Average True Range (ATR)
- BCSF 0.25
- RCUS 0.50
- MACD
- BCSF -0.00
- RCUS 0.12
- Stochastic Oscillator
- BCSF 33.33
- RCUS 99.25
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.